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Abstract: Two serious public health challenges have emerged in the current COVID-19 pandemic
namely, deficits in SARS-CoV-2 variant monitoring and neglect of other co-circulating respiratory
viruses. Additionally, accurate assessment of the evolution, extent, and dynamics of the outbreak
is required to understand the transmission of the virus. To address these challenges, we evaluated
533 samples using a high-throughput next-generation sequencing (NGS) respiratory viral panel (RVP)
that includes 40 viral pathogens. The performance metrics revealed a PPA, NPA, and accuracy of
95.98%, 85.96%, and 94.4%, respectively. The clade for pangolin lineage B that contains certain distant
variants, including P4715L in ORF1ab, Q57H in ORF3a, and S84L in ORF8 covarying with the D614G
spike protein mutation, were the most prevalent early in the pandemic in Georgia, USA. The isolates
from the same county formed paraphyletic groups, indicating virus transmission between counties.
The study demonstrates the clinical and public health utility of the NGS-RVP to identify novel
variants that can provide actionable information to prevent or mitigate emerging viral threats and
models that provide insights into viral transmission patterns and predict transmission/resurgence of
regional outbreaks as well as providing critical information on co-circulating respiratory viruses that
might be independent factors contributing to the global disease burden.
Keywords: respiratory viral panel; SARS-CoV-2; co-circulating virus; Georgia; diagnosis;
epidemiology; COVID-19
1. Introduction
The global society, set back by the COVID-19 pandemic, now in its second year, has
seen over 150 million cases and over 3.1 million COVID-19-related deaths [1]. Conversely,
united efforts around the world in the cultural, economic, and scientific realms, notably
high-throughput diagnostic solutions, therapeutic options, and, more recently, the massive
rollout of vaccinations, with more than 450 M people receiving at least one dose [1], are
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showing promise toward control of the pandemic. For many countries, having weathered
several waves of the pandemic, and with spikes still being anticipated in the future,
persistent effort and surveillance are still required. Human activity and variation in viral
subtypes that determine transmissibility and pathogenicity have largely been implicated for
these trends. Several SARS-CoV-2 variants have been identified, but three recently reported
strains are of significant concern. The 20B/501Y.V1 or VOC 202012/01 variant of the B.1.1.7
(α) lineage that is defined by 17 mutations (14 non-synonymous mutations and 3 deletions)
was identified in the UK [2,3], the 20C/501Y.V2 strain that emerged independently of the
B.1.17 to B1.351 (β) lineage was identified in South Africa, and the B.1.617.2 (δ) variant
has emerged most recently [4,5]. The VOC 202012/01 SARS-CoV-2 strain was 43–90%
more transmissible compared to the preexisting strains and led to “Tier 4” restrictions in
December 2020 in the UK, and the delta variant is emerging as a similar threat [6]. The
emergence of these novel strains imposes the need to sequence the SARS-CoV-2 genome
in clinical laboratories across the entire globe, as any lacunae in monitoring the variation
in the SARS-CoV-2 genome can lead to serious public health consequences. In addition,
another immediate public health deficit pertaining to other respiratory viruses is already
of major concern since co-circulating respiratory viruses other than SARS-CoV-2 largely
remained undocumented for nearly the entire year of 2020.
In the past, pandemics due to novel pathogens have amplified the incidence of res-
piratory tract infections (RTI), leading to morbidity and mortality exceeding the seasonal
levels of the disease. The Global Burden of Disease (2017) data demonstrated that in-
fluenza contributed 11.5% of the total lower respiratory tract infections (LRTIs), leading to
over 9 million hospitalizations and 145,000 deaths across all age groups [7]. Other viral
pathogens, including rhinoviruses, parainfluenza viruses, respiratory syncytial virus, and
adenoviruses, also account for respiratory tract infections of varying severity, as either
mono-infections or coinfections. Coinfection with viral, bacterial, or fungal pathogens
has been associated with disease severity and death in the current pandemic [8]. A meta-
analysis including 30 studies and 3834 COVID-19 patients of all age groups and settings
found that 7% of hospitalized patients had bacterial coinfection, with the most common
being mycoplasma pneumonia, Pseudomonas aeruginosa, and Haemophilus influenza,
and viral coinfections were identified in 3% of the patients [9]. Another meta-analysis
found a slightly higher viral coinfection rate of 7% [10]. A study conducted in California
found a coinfection rate of 20.7% among SARS-CoV-2 positive patients [11], while this was
3.3% in a Chicago study [12]. In both of these studies, rhinovirus and enterovirus were
the most common. In addition to multiplex RT-PCR assays used to identify coinfections,
metagenomics sequencing has demonstrated utility in unbiased identification of coinfection
or colonization [13,14].
Owing to the diversion of resources and supplies to SARS-CoV-2 testing, testing of
viral pathogens that normally cause seasonal RTI has been largely neglected. The current
practice has posed serious public health gaps both at a clinical and epidemiological level,
especially now that the transmission and infective mutations are emerging, and the virus
is persisting to more transmissible variants. Furthermore, as the COVID-19 vaccination
process is underway, the screening of COVID-19 by RT-PCR-based SARS-CoV-2 detection
methods needs to be complemented with two additional monitoring measures. The first is
sequencing the SARS-CoV-2 genome to identify novel variants that can provide actionable
information to prevent or mitigate emerging viral threats, and the second is to test for
co-circulating respiratory viruses that might be independent factors contributing to the
global disease burden. The use of multiple antimicrobial agents in moderate–severely
ill COVID-19 patients can also be rationalized based on such studies. To address these
clinical and public health challenges, we aimed to evaluate the performance of a new high-
throughput next-generation sequencing respirator viral panel (NGS-RVP) that includes
40 viral pathogens; to analyze viral subtypes or mutational variants of SARS-CoV-2 in the
state of Georgia, USA; to develop models to understand the spread of the virus in the state
of Georgia; and to assess the other circulating viruses in the same population.
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2. Materials and Methods
2.1. Study Site and Ethics
The study was performed at Augusta University, Augusta, GA, USA, under IRB
approval. This site is a CLIA accredited laboratory for high-complexity testing and is one
of the main SAR-CoV-2 testing centers in the state. The samples were processed under an
approved HAC by the IRB Committee A (IRB registration # 611298), Augusta University,
GA. Based on the IRB approval, the need for consent was waived, all PHI was removed,
and the data were anonymized before being accessed for the study.
2.2. Samples
This study evaluated a total of 522 samples that included 483 patient samples, 39 syn-
thetic positive control materials (Twist biosciences, San Francisco, CA, USA), and 3 no-
template controls (NTC). The 483 patient samples were previously tested for SAR-CoV-2
by RT-PCR-based COVID-19 diagnostic assay (PerkinElmer Inc. assay (Singapore) (LoD
20 copies/mL)). Of the 483 samples, 471 were NPS and 12 were saliva samples with
398 positive and 85 negatives for SAR-CoV-2 by RT-PCR. For temporal distribution, se-
lected samples included those collected from the month of March to October 2020. In
addition, to ensure samples from the entire state were represented, the state of Georgia was
divided into three arbitrary regions namely, north, southwest, and southeast Georgia, with
31, 72, and 380 samples selected from each of the regions, respectively. Relevant metadata
including age, sex, and ethnicity were recorded. Positive samples with a wide range of Ct
values (N: 6.9–36.8, ORF1ab: 8.7–39.6) were chosen. Included were 39 sample dilutions
of synthetic positive control material with 107 copies/mL, 106 copies/mL, 90 copies/mL,
30 copies/mL and 10 copies/mL.
2.3. Laboratory Processes
2.3.1. RNA Extraction and RT-PCR for SARS-CoV-2
All patient samples were tested for SARS-CoV-2 using an assay based on RNA extrac-
tion followed by TaqMan-based RT-PCR assay to conduct in vitro transcription of SARS-
CoV-2 RNA, DNA amplification, and fluorescence detection (PerkinElmer Inc., Waltham,
MA, USA). The assay targets specific genomic regions of SARS-CoV-2, the nucleocapsid
(N) gene and ORF1ab with an RNA internal control (IC, bacteriophage MS2), to monitor
the processes from nucleic acid extraction to fluorescence detection. The probes are labeled
with FAM, ROX, and VIC dyes to differentiate the fluorescent signals from each target.
The assay validation was performed as per FDA guidelines, following the manufacturer’s
protocol. In brief, a 300 µL sample was used for RNA extraction (chemagic 360 instrument,
PerkinElmer Inc., Waltham, MA, USA), to which 5 µL internal control, 4 µL poly(A) RNA,
10 µL proteinase K, and 300 µL lysis buffer 1 were added. From 60 µL eluate, the RT-PCR
reaction was set up, which included 10 µL of extracted nucleic acid and 5 µL of PCR master
mix. PCR was performed using QuantStudio 3 and 5 Real-Time PCR Systems (Thermo
Fisher Scientific, Waltham, MA, USA). The LoD of this assay is 20 copies/mL.
2.3.2. Next-Generation Sequencing
Library preparation was performed following the Illumina RNA Prep with Enrichment
kits, which leverage BLT technology paired with fast enrichment (cat number 20040537,
Illumina, San Diego, CA, USA). Briefly, 8.5 µL of extracted RNA, by the methodology
described above, was denatured followed by first- and second-strand DNA synthesis.
This was followed by tagmentation, which uses enrichment bead-linked transposomes
(BLT) to tagment double-stranded cDNA. This process fragments cDNA and adds adapter
sequences. After tagmentation, the fragments were purified and amplified to add index
adapter sequences for dual indexing and P7 and P5 sequences for clustering. Four index
sets, A, B, C, and D, each containing 96 unique, single-use Illumina DNA/RNA UD Indexes,
were used. Following clean-up, libraries were quantified using Invitrogen Qubit dsDNA
broad range Assay Kit (Thermo Fischer Scientific, Waltham, MA, USA). Subsequently,
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7.5 µL of the library was used for hybridization using oligos from the respiratory viral
panel. This was followed by bead-based capture of hybridized probes, amplification, clean-
up, and quantification of the enriched library. The viruses targeted by the Respiratory Virus
Oligos Panel V2 (RVOP v2, cat number 20044311, Illumina) are shown in Table 1. As an
additional QC check, representative libraries were analyzed for fragment size using QIaxel
(QIAGEN, Hilden, Germany). Normalized libraries diluted to an equimolar concentration
of 0.8 pM were then pooled into three runs. Using a 150 bp paired-end sequencing approach
and 300 cycles, the libraries were sequenced on the NextSeq 500/550 high-throughput
sequencer using a V2 flow cell kit (Illumina, San Diego, CA, USA).
Table 1. Table showing the viruses included in the enrichment workflow of the Respiratory Virus
Oligos Panel V2.
S. No. Virus
1 Human coronavirus 229E
2 Human coronavirus NL63
3 Human coronavirus OC43
4 Human Corona virus HKU1
5 SARS-CoV-2
6 Human adenovirus B1
7 Human adenovirus C2
8 Human adenovirus E4
9 Human bocavirus 1 (primate bocaparvovirus 1 isolate st2)
10 Human bocavirus 2c PK isolate PK-5510
11 Human bocavirus 3
12 Human parainfluenza virus 1
13 Human parainfluenza virus 2
14 Human parainfluenza virus 3
15 Human parainfluenza virus 4a
16 Human metapneumovirus (CAN97-83)
17 Respiratory syncytial virus (type A)
18 Respiratory syncytial virus 9320 (type B)
19 Influenza A virus (A/Puerto Rico/B/1934(H1N1))
20 Influenza A virus (A/Korea/426/1968(H2N2))
21 Influenza A virus (A/New York/392/2004(H3N2))
22 Influenza A virus (A/goose/Guangdong/1/1996(H5N1))
23 Human bocavirus 4 NI strain HBoV4-NI-385
24 KI polyomavirus Stockholm 60
25 WU polyomavirus
26 Human parechovirus 1 picoBank/HPeV1/A
27 Human parechovirus 6
28 Human rhinovirus A89
29 Human rhinovirus C (strain 024)
30 Human rhinovirus B14
31 Human enterovirus C10 strain AK11
32 Human enterovirus C109 isolate NCA08-4327
33 Influenza A virus (A/Zhejiang/DTIDZJU01/2013(H7N9))
34 Influenza A virus (A/Hong Kong/1073/99(H9N2))
35 Influenza A virus (A/Texas/5020120/99(H3N2))
36 Influenza A virus (A/Michigan/45/2015(H1N1))
37 Influenza B virus (B/Lee/1940)
38 Influenza B virus (B/Wisconsin/60/2008)
39 Influenza B virus (B/Brisbane 60/2008)
40 Influenza B virus (B/Colorado/60/2017)
41 Influenza B virus (B/Washington/02/2019)
2.3.3. Sequence Data Analysis
The run metrics were evaluated on the Basespace app by analyzing cluster density
and Q30 score. Individual FASTQ Sequencing files were then submitted for analysis to the
Dragen pipeline for pathogen detection, available on the DRAGEN RNA Pathogen Detec-
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tion in BaseSpace Sequence analysis (v3.5.16, Illumina, San Diego, CA, USA) that yielded
results for pathogen detection and coverage for each of the viral genomes. In addition,
sequences were also analyzed through the Dragen metagenomics pipeline (Illumina) for
the detection of viruses and bacteria, in addition to the 40 viruses listed in Table 1.
2.3.4. Performance Metric Evaluation
The performance metric was calculated for both clinical and reference control samples
by comparing detection results with the RT-PCR assay results. Seven performance criteria,
viz., positive percentage agreement (PPA), negative percentage agreement (NPA), positive
predictive value (PPV), negative predictive value (NPV), accuracy, false-negative rate
(FNR), and false-positive rate (FPR), were evaluated.
2.3.5. Limit of Detection and Reproducibility Studies
The limit of detection (LoD) studies were conducted as per the FDA guidelines [15].
Briefly, SARS-CoV-2 reference material was sequentially diluted and singly sequenced at
107 copies/mL and 106 copies/mL and at 90 copies/mL, 30 copies/mL, and 10 copies/mL
in triplicate to evaluate both intra-run and inter-run reproducibility. The lowest concentra-
tion detected in all three triplicates was determined as the preliminary LoD. To confirm the
LoD, 20 replicates of preliminary LoD were analyzed and deemed as confirmed if at least
19/20 replicates were detected.
2.3.6. Phylogenetic Clustering of Genomes
Inference and visualization of the phylogeny of the SARS-CoV-2 sequences were per-
formed through the Nextstrain Command-Line Interface (CLI) tool, utilizing the associated
augur and auspice toolkits [1]. To ensure proper phylogenetic inference, the following
sequence exclusion criteria were applied: (i) sequences of length less than 23,000 base pairs
(~77% of the full genome length) were excluded from the analysis; (ii) sequences without
an associated metadata entry were identified and removed; and (iii) after constructing the
phylogeny using a skyline coalescent method and setting a fixed clock rate of 7 × 10−4
substitutions per site per year with a standard deviation of 2 × 10−4, temporal outliers
outside of four interquartile ranges from the root-to-tip vs. time regression were removed.
These steps resulted in a set of 286 sequence tips on the final tree. These parameter deci-
sions were informed by prior analyses of SARS-CoV-2 sequences across North America [2].
These choices were validated by the resultant estimate of the Time of Most Recent Common
Ancestor (TMRCA) confidence interval, which spans from 2 November 2019 to 26 January
2020. Similarly, the estimated clock rate of 8.55 × 10−4substitutions per site per year also
falls within the range of estimates found throughout the literature. The metadata for the




A typical sequencing run of the viral sequencing panel performed on the NextSeq550
platform consists of ~192 samples. In this study, a total of 523 samples were sequenced in
3 runs. The first run included 143 samples sequenced using version one (V1) of the panel.
Runs 2 and 3 included 380 samples sequenced using version two (V2) of the panel. The
quality metrics and clinical performance were evaluated for V2 of the panel that focuses
less reads on human control RNA genes compared to V1, resulting in a more efficient focus
on pathogen RNA genes. Runs 2 and 3 resulted in a cluster density of 221 ± 2.1, and the
Q30 scores were 90.2% and 91.3%, respectively (Figure 1).
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Figure 1. Sequencing performance of the viral sequencing panel performed on NextSeq550 platform. In Qscore distribution
chart: blue bars represent raw clusters and the green bars represent clusters passing filter. In cluster density chart, each
color line represents each lane.
3.2. Performance Metric Evaluation/Analytical Performance
The performance metric was calculated using both the clinical samples and the refer-
ence control material. The PPA and NPA were found to be 95.98% and 85.96%, respectively.
The FPR and FNR were found to be 14.04% and 4.02%, respectively. The accuracy of the
assay was found to be 94.47% (Table 2).
Table 2. Performance metric evaluation of the respiratory viral panel.
Performance Criterion Percentage (%)
Positive percentage agreement (PPA) = TP/(TP + FN) 95.98
Negative percentage agreement (NPA) = TN/(TN + FP) 85.96
Accuracy = TP + TN/All Results 97.48
False negative rate (FNR) = FN/(FN + TP) 4.02
False positive rate (FPR) = FP/(FP + TN) 14.04
3.3. Limit of Detection and Reproducibility Studies
In the preliminary LoD study, all replicates were detected at the five tested concen-
trations using the exact biosciences reference control material. The LoD was determined
to be 10 copies/mL with all 25 replicates detected. The inter- and intra-run evaluation
using 90 copies/mL, 30 copies/mL, and 10 copies/mL of reference material sequenced
in triplicates in two different runs demonstrated high reproducibility, as all replicates
were detected in both runs (Figure 2). Furthermore, all 25 replicates were detected at
10 copies/mL, demonstrating high inter-run reproducibility (Figure 3).
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Figure 3. Reproducibility study using 10 copies/mL.
3.4. Co-Circulating Viruses
Th s study identified that 0.8% (4/483) of patients were infected with viruses other
than SARS-CoV-2. Of the four patients, three had coinfection with human enterovirus C109
isolate NICA08-4327, WU polyomavirus, and KI polyomavirus Stockholm 60 in addition to
SARS-CoV-2. One patient negative for SARS-CoV-2 was found to be infected with human
parainfluenza virus 4a.
3.5. Phylogenetic Clustering of Genomes
The final instance has been posted through the Nextstrain community platform [16].
Using the open-source platform Nextstrain, we built an interactive visualization of the
phylogenic analysis of our SARS-CoV-2 isolates. Two major clades for SARS-CoV-2 that
were named lineages A and B in pangolin lineage can be identified from our current
phylogenetic analysis. Through our Nextstrain thread, it was observed that the clade for
pangolin lineage B contains certain distant variants, including P4715L in ORF1ab, Q57H in
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ORF 3a, and S84L in ORF8 covarying with the D614G spike protein mutation, which were
found to be the most prevalent in the early phase of the pandemic in the state of Georgia.
In addition, we found that isolates from the same county form paraphyletic groups in our
analysis, which indicated virus transmission between counties (Figure 4).
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4. Discussion
T e COVID-19 pandemic has led to massive socio-ec nomic disruption, with a major
impact on healthc re system across the globe. The magnitude of the pan emic required
channeling almost all a ailable resources toward the diagnosis, management, and treatment
of COVID-19. Th diversion of all resources to cope with the pandemic has led to two
maj r knowledg /epidemiological/public health gaps th could further contribute to
the ong ing crisis. The first is the lack of documentation of the variation in the SARS-
CoV-2 genome around the world, and the second is the complete neglect of co-circulating
viruses in the population that contribute to the global disease burd n. This study is an
attempt to address these two major public health lacunae by evaluating the NGS-RVP,
which can identify mutational variants in the SARS-CoV-2 genome and other co-circulating
respiratory viruses in a single assay.
Since December 2019, after the SARS-CoV-2 genome was characterized, various se-
quencing approaches have been utilized to study the virus and, for some technologies,
microbiome and host responses as well. Various NGS technologies have proven their worth
not just in the identification of the exact viral etiology and origin of COVID-19 but also
in diagnostic assay development, vaccine design, and epidemiologic surveillance of viral
transmission and evolution. By employing either shotgun metagenomics, amplicon-based,
or hybrid capture-based sequencing on mid- to ultra-high-throughput platforms and single-
molecule sequencing such as nanopore sequencing, complex clinical and research questions
have been answered [17–19]. These techniques have been found to have almost comparable
genome coverage, with amplicon-based approaches showing high sensitivity for low viral
load samples at a lower cost. Metagenomics and hybrid capture, on the other hand, have
the advantage of unbiased sequencing at a high-throughput scale and coinfection identi-
fication [20]. In this study, we utilized an enrichment workflow, a hybrid-capture-based
approach on a high-throughput platform, and a metagenomic bioinformatic pipeline to
interrogate patient samples that include saliva samples.
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The analytical performance analysis using 522 samples demonstrated the ease of use
and clinical utility of the RVP. The assay had a hands-on time of ~10.5 h and an assay time
of ~3 days. The sequencing run parameters met the recommended threshold values of the
manufacturer, with a high consistency among samples for each parameter (both across runs
and within each run). The ability to sequence both NPS and saliva samples simultaneously
adds a substantial advantage to any clinical laboratory with respect to time and efficiency.
The performance evaluation demonstrated favorable PPA, NPA, FPR, and FNR, with
a high overall accuracy of the panel. The inter- and intra-run evaluation demonstrated
high reproducibility, with an LoD of 10 copies/mL, rendering this assay highly sensitive
and accurate for the detection of the SARS-CoV-2 genome. It is noteworthy that 88.7%
(275/310) and 93.8% (291/310) of positive samples were sequenced with a coverage of
more than 90% and 60% of the SARS-CoV-2 genome, respectively, which is essential for
the phylogenetic clustering and mutational analysis of the genome. The coinfection rate in
this study was low (0.8%), which reflects a low rate of coinfection in this population. Other
studies in different populations have found variable rates of coinfection. A study in the
New York metropolitan area found a coinfection rate by other respiratory pathogens of
less than 3% and infection by other non-SARS-CoV-2 coronaviruses of 13.1% [21].
Genomic sequencing and epidemiological analysis of SARS-CoV-2 are important for
a proper understanding of the evolution and spread of this pathogen in Georgia. To this
end, we built an interactive visualization of the phylogenetic analysis of our samples using
the open-source platform Nextstrain, which could reflect the phylogeny and circulating
diversity during the early SARS epidemic in Georgia. Through our Nextstrain thread,
we found that the clade for pangolin lineage B that contains certain distant variants
covarying with the D614G spike protein mutation had become increasingly prevalent at
the early phase of the pandemic in the state of Georgia. Furthermore, the isolates from the
same county forming a paraphyletic group suggest a prolonged period of unrecognized
community spreading. Such a properly maintained visualization tool can help to improve
public health efforts involving continued exploration of the evolutionary relationships
among SARS-CoV-2 samples and provide a better understanding of genetic diversity
across the whole genome over time. This study demonstrates that genomic epidemiology is
essential in predicting disease transmission and pattern of transmission and that it has the
potential to recognize the imminent resurgence of a regional outbreak. Given the challenges
associated with establishing such a surveillance program, it is essential to develop and
maintain the infrastructure for such analysis for future pandemics.
We propose that as the COVID-19 vaccination process is underway, and with COVID-
19 diagnosis being focused on symptomatic individuals, it is important that representative
samples are sequenced for SARS-CoV-2 genome and variant detection from different
regions of a state/country/world. This would provide actionable information to prevent or
mitigate emerging viral threats and predict transmission/resurgence of regional outbreaks.
Furthermore, it is important to test for co-circulating respiratory viruses that might be
independent factors contributing to the global disease burden.
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